1. Improvement in Atopic Dermatitis Signs and Symptoms With Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.15% or 0.05%: Results From the 52-Week Phase 3 INTEGUMENT-OLE Trial in Patients Aged ≥2 Years
9. Economic Value of Preventing and Treating Comorbid Asthma With Dupilumab in Pediatric Patients With Atopic Dermatitis: A Cost-Offset Model From the US Payer Perspective
11. Growth Improvement in Children 6 to 11 Years With Severe Atopic Dermatitis Treated With Dupilumab Irrespective of Cumulative TCS Use
24. Dupilumab Monotherapy in Patients With Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results From a Phase 4, Open-Label Study
28. Characterization of Atopic Dermatitis Medication Use Before and During Pregnancy in the United States: Results From the Dupi PODS Study
33. Effectiveness and Safety of Upadacitinib in Canadian Adult Patients With Atopic Dermatitis Who Were Inadequate Responders or Intolerant to Dupilumab: Results From the CAN UpTIMISE Phase 4 Multicentre Study
42. Real-World Effectiveness of Upadacitinib in Moderate-toSevere Atopic Dermatitis (AD) in Bio-Experienced and BioNaïve Patients: Results from Longitudinal Analyses of the CorEvitas AD Registry
48. Real-World Assessment of Systemic Treatment Usage for Atopic Dermatitis
66. Social Determinants in Early Childhood Atopic Dermatitis: Insights from a Medicaid-Eligible Cohort in Rochester, NY
69. Flexible Dosing of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Initial Results From the Real-World–Simulating Expanded Access Protocol Study, JADE REAL